论文部分内容阅读
目的观察重组人B型利钠肽治疗慢性心力衰竭失代偿期急性加重的临床疗效。方法选取2013年6月—2016年2月延安大学附属医院收治的慢性心力衰竭失代偿期急性加重患者110例,采用随机数字表法分为对照组和观察组,每组55例。两组患者入院后均给予常规抗心力衰竭治疗,观察组患者在此基础上给予重组人B型利钠肽治疗。比较两组患者临床疗效、治疗前后心功能指标及生化指标、治疗期间不良反应发生率。结果观察组患者临床疗效优于对照组(P<0.05)。两组患者治疗前左心室射血分数(LVEF)、左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)、左心室短轴缩短率(LVSF)比较,差异均无统计学意义(P>0.05);观察组患者治疗后LVEF、LVSF高于对照组,LVESD、LVEDD低于对照组(P<0.05)。两组患者治疗前N末端B型利钠肽原(NT-pro BNP)、胱抑素C(Cys C)、转化生长因子β(TGF-β)水平比较,差异无统计学意义(P>0.05);观察组患者治疗后NT-pro BNP、Cys C、TGF-β水平均低于对照组(P<0.05)。两组患者治疗期间不良反应发生率比较,差异无统计学意义(P>0.05)。结论重组人B型利钠肽治疗慢性心力衰竭失代偿期急性加重的临床疗效确切,可有效改善患者心功能及心力衰竭症状,且安全性较高。
Objective To observe the clinical efficacy of recombinant human B-type natriuretic peptide in the treatment of acute exacerbation of chronic heart failure. Methods Totally 110 patients with acute exacerbation of chronic heart failure admitted to Yan’an University Affiliated Hospital from June 2013 to February 2016 were randomly divided into control group and observation group with 55 cases in each group. Both groups were given conventional anti-heart failure treatment after admission. Patients in the observation group were given recombinant human B-type natriuretic peptide on this basis. The clinical curative effect, heart function index and biochemical index before and after treatment were compared between two groups. The incidence of adverse reactions during the treatment period was compared. Results The clinical efficacy of the observation group was better than that of the control group (P <0.05). There was no significant difference in LVEF, LVESD, LVEDD and LVSF between the two groups before treatment (P> 0.05) P> 0.05). The LVEF and LVSF in the observation group were higher than those in the control group, and LVESD and LVEDD were lower than those in the control group (P <0.05). There was no significant difference in the levels of N-terminal pro-brain natriuretic peptide (NT-pro BNP), cystatin C (Cys C) and transforming growth factor β (TGF-β) between the two groups before treatment ). The levels of NT-pro BNP, Cys C and TGF-β in the observation group were lower than those in the control group (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups during treatment (P> 0.05). Conclusions The clinical efficacy of recombinant human B-type natriuretic peptide in the treatment of acute decompensation of chronic heart failure is definite. It can effectively improve the symptoms of patients with heart failure and heart failure and is safe.